Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein–Barr virus vaccine in healthy adults

This publication has 25 references indexed in Scilit:

• Stress-associated changes in the steady-state expression of latent Epstein–Barr virus: Implications for chronic fatigue syndrome and cancer
  Brain, Behavior, and Immunity, 2004
• Direct killing of Epstein-Barr virus (EBV)–infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1
  Blood, 2004
• CD4⁺T-Cell Effectors Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation
  Journal of Virology, 2001
• The Mechanism of Action of Cyclosporin A and FK506
  Clinical Immunology and Immunopathology, 1996
• Replication-defective recombinant adenovirus expressing the Epstein--Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin
  Journal of General Virology, 1993
• Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
  The Journal of Experimental Medicine, 1992
• Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector
  Journal of General Virology, 1992
• Validation of a first‐generation epstein‐barr virus vaccine preparation suitable for human use
  Journal of Medical Virology, 1989
• Recombinant vaccinia virus expressing epstein‐barr virus glycoprotein gp340 protects cottontop tamarins against EB virus‐induced malignant lymphomas
  Journal of Medical Virology, 1988
• Protection of cottontop tamarins against Epstein–Barr virus-induced malignant lymphoma by a prototype subunit vaccine
  Nature, 1985